Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics

By afschroeder • February 20, 2026

Rodriguez GE, Zhao Y, Nishiga Y, Peprah F, Shen J, Abhiraman GC, Ogishi M, Zhang C, Saco J, Waghray D, Serasanambati M, Torres L, Simone BW, Su L, Wilson SC, Yang A, Sun Q, Picton L, Saxton RA, Bhandarkar V, Lee MJ, Andrews E, Jiang H, Obenaus M, Yen M, Atajanova T, Blish CA, Spranger S, Wherry EJ, Kirane A, Ribas A, Raulet DH, Kalbasi A, Dougan SK, Dougan M, Sage J, Garcia KC. Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics. Science. 2026 Feb 19:eadx9954. doi: 10.1126/science.adx9954. Epub ahead of print. PMID: 41712697.

Tags: Hematology/Oncology, Publications

Related Posts

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial

Girard N, Goldman J, Lu S, Bar J, Horinouchi H, Daaboul N, Liu C, Çiçin I, Katgi N, Zer A, Ciuleanu T, Reinmuth N, Planchard[...]

Local partisan context and mental health

Baxter-King R, Brown JR, Enos RD, Naeim A, Vavreck L. Local partisan context and mental health. Proc Natl Acad Sci U S A. 2026 Jul[...]

Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD

Okamoto I, Cho BC, Goldberg SB, Goldman JW, de Langen AJ, Piotrowska Z, Riess JW, Yu HA, Garcia Campelo MR, Cetnar J, Kim YJ, Novello[...]